Christopher Song, MD
Otolaryngology · Brooklyn, NYNPI 1770568818
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $270, 9.5 times the $29 reported in 2019. That places this record below the midpoint for otolaryngology clinicians in NY, where the typical reported total is $1,040.
Across 40 payments — averaging $23.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$120
- GSK$111
- Optinose US, Inc.$90
- Regeneron Healthcare Solutions, Inc.$77
- Sanofi$72
- Amgen$71
- plus $417 from 10 others
Across 1 payment — averaging $53,333 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$53K
What the payments were for
- Food & beverage$957100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $120 |
| GSK | 4 | $111 |
| Optinose US, Inc. | 4 | $90 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Sanofi | 3 | $72 |
| Amgen(2 entities) | 3 | $71 |
| Alk-abello, Inc | 4 | $71 |
| Novartis | 3 | $69 |
| Hikma Pharmaceuticals USA | 1 | $51 |
| Kaleo, Inc. | 2 | $50 |
| Stryker | 1 | $49 |
| Genentech USA, Inc. | 2 | $45 |
| Integra Lifesciences Corporation | 1 | $30 |
| Pfizer | 1 | $19 |
| Cranial Technologies, Inc | 1 | $18 |
| Phadia US Inc. | 1 | $16 |
How this compares
$957 in reported general payments places this provider in the 45th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 361 | $4,752 |
| Fluocinolone Acetonide Oil | 82 | $2,730 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 23 | $2,724 |
| Olopatadine Hcl | 23 | $2,282 |
| Ipratropium Bromide | 64 | $2,073 |
| Azelastine Hcl | 36 | $939 |
| Ofloxacin | 32 | $550 |
| Mometasone Furoate | 45 | $521 |
| Methylprednisolone | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Brooklyn
- Michael SingerBrooklyn$39K
- Boris BentsianovBrooklyn$19K
- Sydney ButtsBrooklyn$12K
- Robert KellmanSyracuse$2.5M
- Roheen RaithathaNew York$830K
- Nora PerkinsAlbany$300K
- Moshe EphratNew Hyde Park$250K
- Gavin SetzenAlbany$243K
- Habibullah JamalRye Brook$179K
- Albert JenFlushing$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.